BOSTON - A plaintiff expert who testified that Abbott Laboratories failed to adequately warn that its Humira biological arthritis drug has a risk of lymphoma is not qualified to do so, a Massachusetts federal judge ruled Sept. 27 in granting summary judgment for the defendant (Maureen E. Calisi v. Abbott Laboratories, No. 11-10671, D. Mass.; 2013 U.S. Dist. LEXIS 139257).